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Abstract
High prevalence of non-alcoholic fatty liver disease 
(NAFLD) and very diverse outcomes that are related to 
disease form and severity at presentation have made 
the search for noninvasive diagnostic tools in NAFLD 
one of the areas with most intense development in 
hepatology today. Various methods have been investi-
gated in the recent years, including imaging methods 
like ultrasound and magnetic resonance imaging, differ-
ent forms of liver stiffness measurement, various bio-
markers of necroinflammatory processes (acute phase 
reactants, cytokines, markers of apoptosis), hyaluronic 
acid and other biomarkers of liver fibrosis. Multicom-
ponent tests, scoring systems and diagnostic panels 
were also developed with the purposes of differentiat-
ing non-alcoholic steatohepatitis from simple steatosis 
or discriminating between various fibrosis stages. In all 
of the cases, performance of noninvasive methods was 
compared with liver biopsy, which is still considered 
to be a gold standard in diagnosis, but is by itself far 
from a perfect comparative measure. We present here 
the overview of the published data on various noninva-
sive diagnostic tools, some of which appear to be very 
promising, and we address as well some of still unre-
solved issues in this interesting field.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Finding a means to noninvasive diagnosis of  non-alco-
holic fatty liver disease (NAFLD) and its entities has 
been the aim of  many research efforts since recently, and 
seems to remain a very much needed goal among many 
clinicians and researchers in the field of  hepatology. Why 
is it that way?
NAFLD is today considered to be the most common 
liver disease in adults. The prevalence of  NAFLD in gen-
eral population is very high, in the range of  15%-30% ac-
cording to various studies, and is even increasing, due to 
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the rising prevalence of  diabetes and obesity[1]. Spectrum 
of  NAFLD includes two entities with very different nat-
ural course and prognosis: simple steatosis, which mostly 
has a benign non-progressive course and good prognosis, 
and non-alcoholic steatohepatitis (NASH), which dem-
onstrates progression of  fibrosis in about 30%-40% of  
patients and has a proven potential to eventually lead to 
cirrhosis and end-stage liver disease including hepatocel-
lular carcinoma[2-4]. NASH seems to be present in a sur-
prisingly high proportion of  NAFLD patients, including 
40% to 75% of  cases with elevated aminotransferase lev-
els, those data coming from recent studies using current 
histological definitions and including substantial number 
of  patients[2,5,6]. In studies of  liver biopsy findings from 
apparently healthy living liver donor candidates, the pro-
portion of  NASH among patients with newly discovered 
NAFLD was about 30%[7]. Even in patients with normal 
aminotransferase levels, proportion of  NASH among NA-
FLD cases seems to be almost the same, and the whole 
spectrum of  NAFLD including advanced fibrosis and 
cirrhosis has been observed in patients with completely 
normal laboratory findings[6,8,9].
Liver biopsy is still considered the gold standard in 
diagnosis and the only reliable tool for distinguishing 
NASH from simple steatosis and for grading and stag-
ing the disease, providing important information about 
severity of  steatosis, lobular inflammation, hepatocellular 
ballooning, and degree of  fibrosis[10]. Minimal histological 
criteria for NASH include steatosis, hepatocyte injury (in 
the form of  ballooning or apoptosis) and lobular inflam-
mation. Similarly to other chronic liver diseases, fibrosis is 
usually divided histologically in four stages: perisinusoidal 
fibrosis (F1), perisinusoidal and periportal fibrosis (F2), 
bridging fibrosis (F3) and cirrhosis (F4). Liver biopsy also 
has several negative aspects: it is invasive, unpleasant for 
patients, it usually includes hospitalization and a day or 
two lost at work, and the adequate interpretation of  the 
specimen requires a pathologist with expertise in hepa-
topathology, which altogether makes it a costly and time-
consuming procedure. Another significant drawback of  
liver biopsy, and in medical terms the most important one 
is its substantial sampling variability, which has been con-
sistently proven for several chronic liver diseases includ-
ing NAFLD. In a well-designed study by Ratziu et al[11], 
the negative predictive value of  a single biopsy for the 
diagnosis of  NASH was calculated to be only 74%.
Considering the mentioned high prevalence of  NA-
FLD in the general population, and the fact that every 
patient with NAFLD including the one with normal ami-
notransferases can potentially have NASH, we come to 
the conclusion that it would be necessary to perform liver 
biopsy in about one fourth of  the whole Western popula-
tion. This is clearly not feasible, but is it necessary? Until 
recently, many have advocated against the routine use 
of  liver biopsy for patients with NAFLD because fatty 
liver is still considered by many to be a benign condition-
although many studies have now clearly indicated a pro-
gressive course in a proportion of  patients with NASH. 
Another reason for avoiding biopsy and definite diagno-
sis was the lack of  established pharmacological treatment 
options which would have proven efficacy in preventing 
progression or leading to regression of  disease.
Although there are still no generally approved treat-
ments for NASH, several treatment options have demon-
strated efficacy in various clinical trials, and for example 
recently published results of  the randomized multicenter 
pioglitazone vs vitamin E vs placebo for the treatment of  
nondiabetic patients with nonalcoholic steatohepatitis 
(PIVENS) trial have provided substantial evidence for 
the previously suggested efficacy of  vitamin E (and to a 
lesser extent pioglitazone) in inducing histologic improve-
ment of  NASH[12]. Hopefully, we could soon expect to 
have several efficient treatment options available. All 
of  this pretty much eliminates the validity of  approach 
where NASH remains undiagnosed, which currently does 
happen in many clinical settings, e.g., in patients with ac-
cidental ultrasonographic finding of  fatty liver and even 
patients with mildly elevated transaminase levels and 
known NAFLD risk factors who are very often not in-
vestigated any further. 
The necessity of  diagnosing NASH and the propor-
tion of  the population affected lead to a logical conclu-
sion that a need for a reliable noninvasive tool in NAFLD 
diagnosis is highly urgent. Ideal noninvasive tool would 
be able to distinguish NASH from simple steatosis and 
allow for grading and staging of  disease, which would 
largely facilitate screening of  population at risk. Develop-
ment of  noninvasive tools would also enable monitor-
ing of  disease course and progression and evaluation of  
response to therapy, both in routine practice and in the 
setting of  clinical trials, which is currently only possible 
with a follow-up liver biopsy. Another very important, 
and somewhat disregarded point, is that an efficient bio-
marker or set of  biomarkers would accurately reflect the 
inflammatory and fibrotic processes on the level of  the 
whole of  liver parenchyma, thereby increasing the diag-
nostic accuracy and resolving the problem of  sampling 
variability intrinsic to liver biopsy, which represents only 
about 1/50.000 part of  the organ which is not homoge-
neously affected by disease features.
In the text below, we present the current level of  
knowledge and progress regarding the noninvasive di-
agnostic tools that have been studied in the context of  
NAFLD (Table 1).
ROUTINE LABORATORY TESTS
Patients with NAFLD are mostly asymptomatic and the 
disease is usually suspected based on either hyperechoic 
liver appearance on abdominal ultrasound or mild to 
moderate increases in liver enzyme levels. These are usu-
ally the only aberrations that can be encountered in this 
patient population (apart from signs of  associated con-
ditions like elevated glucose or lipid levels), and a large 
proportion of  patients has completely normal laboratory 
findings. Hypoalbuminemia, prolonged prothrombin time, 
and hyperbilirubinemia are parameters of  impaired liver 
function and occur only in patients who have already de-
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veloped cirrhosis. Most commonly elevated enzymes are 
alanine aminotransferase (ALT) and γ-glutamyltransferase 
(GGT), while aspartate aminotransferase (AST) elevation 
is less frequent and when pronounced may indicate pres-
ence of  advanced fibrosis[13]. Many studies have tried to 
correlate liver enzyme levels with histological severity and 
progression of  disease, and various results have been ob-
tained. In some cases ALT, in other AST or GGT levels 
demonstrated best correlation with severity of  inflam-
mation or fibrosis and their progression/regression on 
follow-up biopsies[4,14-16]. Equally important, the full spec-
trum of  NAFLD including severe inflammation and fi-
brosis was proven to occur with almost similar frequency 
in patients with completely normal liver enzymes[8,9].
IMAGING METHODS
Imaging modalities frequently used in the diagnosis of  
NAFLD include ultrasound, computed tomography and 
magnetic resonance imaging (MRI). While they are all 
very sensitive (80%-100%) and specific in detection of  
steatosis, none of  them can effectively distinguish simple 
steatosis from NASH or determine the degree of  fibro-
sis[17]. Nevertheless, MRI is more sensitive than ultrasound 
in detecting lesser degrees of  hepatic steatosis, and new 
techniques in MRI are constantly being developed that 
provide additional data on different tissue parameters. 
One of  them is magnetic resonance (MR) elastography, 
which estimates liver tissue stiffness by imaging the prop-
agation of  induced shear waves with a modified phase-
contrast MR sequence. This technique was shown to have 
an excellent predictive value for excluding fibrosis, while 
sensitivity and specificity for discriminating between mild 
and more severe fibrosis was around 85%[18]. A recent 
study investigated the performance of  MR elastography 
in 58 patients with NAFLD and demonstrated very high 
accuracy with under the receiver operated curve (AUROC) 
of  0.93 for discriminating patients with NASH and those 
with simple steatosis, with a sensitivity of  94% and a 
specificity 73% by using a threshold of  2.74 kPa[19]. The 
future advances in MRI technology including hepatic flow 
parameters and diffusion-weighted MRI may hopefully 
provide more MR-based tools for liver fibrosis detec-
tion. Ultrasound has also demonstrated the potential for 
improvement in diagnosis of  NAFLD and NASH. Apart 
from ultrasound-based elastography, use of  ultrasound 
contrast agents has been studied in this scenario, and 
signal intensity after contrast administration was shown 
to be significantly lower in NASH when compared with 
simple steatosis and normal liver[20].
LIVER STIFFNESS MEASUREMENT
Transient elastography (FibroScan®, EchoSens, Paris, 
France) is a relatively novel technique which measures 
liver tissue elasticity by measuring the speed of  propaga-
tion of  probe-induced vibrations through parenchyma by 
ultrasound. Elasticity shows significant correlation with 
degree of  liver fibrosis, and FibroScan is considered to 
produce a reliable prediction of  higher degrees of  liver 
fibrosis. The method was first assessed in population of  
patients with hepatitis C, and after evaluation in multiple 
studies it has been introduced into clinical practice. A 
survey performed four years ago in France showed that 
about a third of  hepatologists was using it (mostly in 
evaluation of  patients with hepatitis C), and the method 
is now gaining increasing popularity in other countries 
as well[21]. More recent studies have assessed transient 
elastography in population of  patients with NAFLD, and 
obtained results that are similar to those from studies in 
hepatitis C[22-24]. A consistent increase in liver stiffness 
with increasing fibrosis stage was observed, and the larg-
est study, performed by Wong et al[22], obtained AUROC 
values of  0.93 for advanced fibrosis and 0.95 for cirrho-
sis. When the liver stiffness cut-off  was set at 7.9 kPa, 
negative predictive value for advanced fibrosis was excel-
lent (97%), and could be applied to 60% of  the popula-
tion. On the other side, positive predictive value of  hav-
ing advanced fibrosis or cirrhosis was at best only 72.4%, 
at the 9.6 kPa cut-off. Accuracy of  FibroScan in detect-
ing significant fibrosis (defined as at least perisinusoidal 
and portal/periportal fibrosis) was poor, as was expected 
from previous experience. 
Several meta-analyses have assessed performance of  
transient elastography in fibrosis detection, consisting 
Table 1  Overview of noninvasive methods in diagnosis of 
liver disease severity that have been evaluated in the context 
of non-alcoholic fatty liver disease
Routine laboratory tests
   Liver enzymes
   Parameters of liver dysfunction
Imaging methods
   Ultrasound
   Computed tomography
   Magnetic resonance imaging
   Magnetic resonance elastography
Liver stiffness measurement
   Transient elastography (FibroScan)
   Acoustic radiation force impulse shear wave imaging
Biomarkers of necroinflammation
   Cytokeratin 18 fragments
   High-sensitivity C-reactive protein
   Interleukin-6 
   C-C chemokine ligand 2 
   Plasma pentraxin 3
   Oxidative stress measurement
   Tumor necrosis factor-α 
   Adiponectin
   Insulin resistance measurement
Multicomponent tests for diagnosis of non-alcoholic steatohepatitis
   Nash test
   Non-alcoholic steatohepatitis clinical scoring system for morbid obesity
   Model by Miele et al[61]
Biomarkers of fibrosis
   Hyaluronic acid
   Laminin
   Type Ⅵ collagen 7S domain
Multicomponent panels for diagnosis of fibrosis
   Fibrotest
   Non-alcoholic fatty liver disease fibrosis score
   European liver fibrosis panel/enhanced liver fibrosis panel 
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mostly of  studies on hepatitis C patients. They have 
shown generally very good diagnostic accuracy in detect-
ing cirrhosis and somewhat lesser precision in excluding 
advanced fibrosis, while they demonstrated substantial het-
erogeneity in diagnosis of  significant fibrosis (F ≥ 2)[25,26]. 
Importantly, variation in cut-off  values of  liver stiffness 
has been large and these values still require validation. In 
conclusion, due to the relatively low specificity, the value 
of  transient elastography seems to remain in ruling out 
cirrhosis and advanced fibrosis in patients with low liver 
stiffness values, while patients with intermediate values 
would still require liver biopsy for correct classification, 
and the proportion of  patients with high stiffness values 
who are misclassified is not negligible. It is also impor-
tant to take into account that the population of  patients 
that is usually encountered in clinical practice does not 
have advanced fibrosis or cirrhosis in large proportions, 
and diagnosis of  lesser degrees of  fibrosis is equally im-
portant in estimating the risk for liver-related morbidity 
and mortality. A large study that evaluated frequency and 
reasons of  failure to obtain the elasticity measurement 
found that FibroScan was feasible in over 95% of  the 
patients, and the only factor associated with failure was 
body mass index greater than 28[27]. Failure occurs due to 
the elastic and ultrasound wave attenuation by subcutane-
ous fat, and while this may not be a significant issue in 
other chronic liver diseases, it is an important limitation 
in patients with NAFLD, considering the prevalence of  
obesity in this population. In the study by Wong et al[22], 
measurement could not be obtained in over 10% of  cas-
es, which significantly reduced diagnostic accuracy when 
the ‘intention-to-diagnose’ analysis was performed. 
Another noninvasive method of  assessing tissue stiff-
ness, acoustic radiation force impulse (ARFI) shear wave 
imaging, was recently assessed in a couple of  studies with 
NAFLD patients[28,29]. This ultrasound-based technique 
estimates the tissue stiffness by measuring transient tis-
sue deformations of  several microns which are induced 
in the liver parenchyma by acoustic radiation force. In a 
study on 172 NAFLD patients by Palmeri et al[29], ARFI 
imaging distinguished low (Stages 0-2) from high (Stage 
3-4) fibrosis stages with a sensitivity and a specificity of  
around 90% (AUROC of  0.90). Body mass index over 
40 kg/m2 was not a limiting factor for ARFI imaging, 
which overcomes part of  the problems associated with 
FibroScan. When compared to FibroScan, ARFI imaging 
demonstrated similar diagnostic performance[28,30].
BIOMARKERS OF NECROINFLAMMATION
Most intense research is now being focused on biomark-
ers, measurable serum parameters that reflect the intensity 
of  inflammatory processes and hepatocyte necrosis, as 
well as the ones that reflect extracellular matrix remodel-
ling and collagen deposition. Ideally, an excellent biomark-
er would be specific for liver and accurately reflect the 
underlying pathogenetic processes on the level of  whole 
organ, and thus be an even more precise indicator of  the 
disease than liver biopsy, which is prone to sampling vari-
ability and interpretation biases as described earlier.
Cytokeratin 18 fragments
Apoptosis is an important mechanism in pathogenesis 
of  NASH, and its initiation leads to activation of  caspase 
family of  intracellular proteases which then cleave differ-
ent intracellular proteins including cytokeratin 18 (CK-18), 
the major intermediate filament protein in hepatocytes. 
By measurement of  CK-18 fragments hepatocyte apop-
tosis can be quantified, and this method was tested as a 
noninvasive tool in NASH diagnosis in several studies. 
Initial results were very promising, as Wieckowska et al[31] 
demonstrated a striking increase in serum CK-18 frag-
ment levels in patients with definitive NASH, as well as 
their high diagnostic accuracy for differentiating between 
NASH and simple steatosis or normal liver, with AU-
ROC of  0.93 and positive and negative predictive value 
of  95.0% and 89.5%, respectively. However, this study 
included only 39 patients, and the larger validation study 
that was subsequently undertaken and included 139 pa-
tients obtained less favourable results: median CK-18 
fragment levels in NASH cases were now only 335 U/L 
(compared to 765 U/L in the first study, and to about 
200 U/L in non-NASH cases in both studies), and di-
agnostic performance was expectedly poorer (calculated 
AUROC was 0.83 and sensitivity for diagnosing NASH 
was at best 77%, with the specificity rising above 90% 
only at the highest tested cut-off  value)[32]. Nevertheless, 
CK-18 fragment levels showed very good correlation 
with NASH, fibrosis and NAS (NAFLD activity score), 
and similar results were reported from other groups as 
well, supporting its potential role as a noninvasive tool 
in NAFLD[33-35]. Even more importantly, in the study by 
Diab et al[35,36] on 99 patients who underwent bariatric sur-
gery, CK-18 fragment levels showed a significant decrease 
6 mo postoperatively, and in another study changes in 
CK-18 fragment levels closely paralleled changes in NAS 
on follow-up biopsy. These findings indicate the potential 
use of  CK-18 fragment levels in the follow-up of  patients 
with NASH, including evaluation of  response to therapy. 
This certainly requires further attention, as it could pos-
sibly lead us closer to the goal of  eliminating the need 
for second liver biopsy and thus facilitating design and 
conductance of  clinical trials, as well as enhancing patient 
follow-up in clinical practice.
High-sensitivity C-reactive protein
C-reactive protein (CRP) is an acute-phase reactant pro-
duced by the liver in many inflammatory conditions, and 
based on the hypothesis that NASH is associated with 
low-grade systemic inflammation, several studies have 
compared high-sensitivity CRP levels in patients with NA-
FLD. Two studies found that hs-CRP levels were signifi-
cantly higher in cases with NASH compared to those with 
simple steatosis, and hs-CRP also correlated well with 
presence of  advanced fibrosis[37,38]. However, a study per-
formed earlier concluded that measurement of  hs-CRP 
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was not useful in predicting the histological severity of  
NAFLD, as there was no relationship between the levels 
of  hs-CRP and the grades of  steatosis, necroinflamma-
tion or fibrosis[39]. Further investigation including testing 
of  diagnostic accuracy is needed before definite conclu-
sions can be reached about usefulness of  this marker in 
NAFLD. 
Interleukin-6 and C-C chemokine ligand 2 
Interleukin-6 (IL-6) is a proinflammatory cytokine that is 
involved in NAFLD pathogenesis, and Wieckowska et al[40] 
demonstrated a markedly increased IL-6 expression in 
liver tissue of  patients with NASH as compared to simple 
steatosis or normal liver, with a positive correlation with 
severity of  inflammation and fibrosis. Plasma IL-6 levels 
that were parallely measured in this study correlated well 
with liver IL-6 expression. In another study, IL-6 was 
among several serum markers evaluated in 47 NAFLD 
patients and 30 controls, and it was significantly increased 
in patients with NAFLD as compared to controls, but not 
in NASH compared to simple steatosis[41]. This study also 
evaluated serum levels of  C-C chemokine ligand 2 (CCL2), 
a chemokine responsible for monocyte/macrophage infil-
tration of  liver and maintaining hepatic inflammation and 
fibrogenesis, and found that it was significantly elevated 
in patients with NASH compared to simple steatosis, but 
diagnostic performance of  CCL2 levels was not tested. 
In a recent study, pharmacological inhibition of  CCL2 
had an effect on reduction of  hepatic steatosis in a mu-
rine model, and CCL2 will presumably see some further 
investigation in the context of  NAFLD[42].
Plasma pentraxin 3
Plasma pentraxin 3 is a novel marker of  systemic inflam-
mation from pentraxin family of  acute-phase proteins 
that is produced by diverse cell types in response to pro-
inflammatory cytokines[43]. Yoneda et al[44] have evaluated 
pentraxin 3 levels in 70 patients with NAFLD, and found 
that they were significantly higher in cases with NASH 
compared to non-NASH, with the AUROC value of  0.75 
for NASH detection. Pentraxin 3 levels also correlated 
well with the stage of  fibrosis. These findings should 
provide basis for additional evaluation of  this marker in 
other NAFLD patient cohorts. 
Oxidative stress
Oxidative stress is one of  the key mechanisms in NASH 
pathogenesis, and several studies have measured systemic 
markers of  oxidative stress status in NAFLD patients 
and compared them between cases with NASH and con-
trols[45-47]. Different methods for measurement of  oxida-
tive stress have been used (measurement of  levels of  
lipid peroxidation products, levels of  antioxidant defence 
systems like vitamin E, glutathione peroxidase and su-
peroxide dismutase activities, antioxidant capacity of  the 
plasma and total plasma peroxide concentrations), and 
studies produced disparate results. Based on the current 
data, there is no doubt that oxidative stress is present in 
NASH, but the utility of  its measurement as a noninva-
sive tool in NAFLD diagnosis probably does not have 
any clinical value.
Tumor necrosis factor-α and adiponectin
Tumor necrosis factor (TNF)-α and adiponectin are cy-
tokines which have been proven to play important roles 
in NAFLD pathogenesis, and the serum levels of  these 
cytokines were determined in patients with NAFLD 
and correlated to disease severity in multiple studies[48-52]. 
However, diagnostic accuracy in discerning NASH from 
simple steatosis and the potential for noninvasive use in 
diagnosis were generally not evaluated, and the data on 
diagnostic performance of  this cytokines are not avail-
able. As of  the published results, most of  the studies 
demonstrated correlation of  lower adiponectin levels 
with presence of  NAFLD compared to healthy controls, 
presence of  NASH compared to simple steatosis, and 
with histological severity of  the disease, while levels of  
TNF-α and its soluble receptor were most often not 
significantly different between patients with NASH and 
patients with simple steatosis or controls. Thus, the po-
tential for clinical use of  this cytokines as noninvasive 
tools for diagnosis of  NASH is questionable.
Insulin resistance
Insulin resistance state leads to increased lipolysis and 
free fatty acid flux to the liver, and elevated plasma glu-
cose and insulin levels promote de novo fatty acid synthesis 
and impair β-oxidation, contributing to the development 
of  hepatic steatosis. Although it is not clear whether 
insulin resistance causes hepatic steatosis or the liver 
fat accumulation represents the primary event leading 
to peripheral insulin resistance, there is no doubt that it 
plays an important role in the pathogenesis of  NAFLD. 
Large population studies have shown that almost all of  
the NAFLD patients were insulin resistant according to 
the homeostasis model assessment of  insulin resistance 
(HOMA-IR)[53]. Additionaly, the potential of  insulin resis-
tance measurement as a noninvasive diagnostic tool was 
also evaluated. In a study by Shimada et al[54], the authors 
tested the diagnostic performance of  adiponectin, insulin 
resistance measured by HOMA-IR, and type Ⅳ collagen 
7S in discriminating NASH from simple steatosis. While 
performance of  each of  these markers individually wasn’t 
great, sensitivity of  the combination of  three markers 
was 94%, with a specificity of  74%.
Although insulin resistance has been usually associ-
ated with type 2 diabetes, it can also be present in type 1 
diabetic patients[55]. The euglycemic insulin clamp tech-
nique which represents the gold standard for identify-
ing type 1 diabetic patients who are insulin resistant is 
impractical for routine clinical use, and insulin resistance 
in type 1 diabetic patients was often recognized only by 
higher insulin requirements. Recent introduction of  a val-
idated method for estimated glucose disposal rate (eGDR) 
measurement based on clinical parameters has allowed its 
easier assessment in a clinical setting[56]. A recently pub-
Baršić N et al . Noninvasive diagnosis of NAFLD
3950 August 14, 2012|Volume 18|Issue 30|WJG|www.wjgnet.com
lished study demonstrated that NAFLD markers were 
associated with insulin resistance measured by eGDR in 
type 1 diabetic patients. NAFLD associated markers (ALT, 
AST, alkaline phosphatase, GGT and ferritin) worsened 
in parallel with the decline in insulin sensitivity and after 
adjustment for covariates, ALT, AST and alkaline phos-
phatase were independent predictors of  insulin resis-
tance[57].
Multicomponent tests
There have been several attempts at constructing a panel 
of  clinical and laboratory parameters that would, when 
combined using a formula or a scoring system, result in 
a value that enables distinguishing bewteen NASH and 
simple steatosis. The most advanced attempt was a study 
by the French group specialized at developing diagnostic 
models for various liver conditions, who constructed a 
complex test (NashTest) which combines 13 parameters 
(age, sex, height, weight, triglycerides, cholesterol, α2-
macroglobulin, apolipoprotein A1, haptoglobin, GGT, 
ALT, AST and bilirubin) into a patented algorithm[58]. 
Their design and validation study included 257 patients 
and 383 controls, and the NashTest had AUROC of  0.79 
[95% confidence interval (CI) 0.69-0.86], with sensitivity 
for NASH (using criteria by Kleiner et al[59]) of  only 33% 
and positive predictive value of  66%. The results were 
somewhat better when subgroups with borderline NASH 
and NASH were combined, the sensitivity rising to 88% 
and positive predictive value to 74%. In another study, a 
clinical scoring system was developed based on the results 
of  multivariate analysis in a group of  morbidly obese 
patients that underwent intraoperative liver biopsy at bar-
iatric surgery[60]. The proposed NASH Clinical Scoring 
System for Morbid Obesity included 6 clinical variables 
(hypertension, diabetes, AST, ALT, sleep apnea and non-
black race) and was used to stratify morbidly obese into 
4 groups regarding the risk for presence of  NASH (low, 
intermediate, high and very high). In the studied group, 
the proportion of  patients with low-risk score who had 
NASH was 13%, while it was 80% in those with very 
high-risk score. Recently, Miele et al[61] measured several 
markers of  liver fibrosis in a cohort of  46 patients with 
NAFLD, and constructed a mathematical model based 
on the results of  multivariate analysis that included age, 
hyaluronic acid and tissue inhibitor of  metalloproteinase 
1 levels. A specific cut-off  value identified patients with 
NASH with 86% sensitivity, and negative and positive 
predictive values of  96% and 60%. This model could 
potentially be useful in excluding patients with negative 
values from liver biopsy consideration if  these findings 
are confirmed in larger independent studies.
BIOMARKERS OF FIBROSIS
As with other chronic liver diseases, the most important 
indicator of  severity and progression of  liver damage 
in NAFLD is the presence and degree of  liver fibrosis. 
Estimation of  fibrosis is therefore essential in the diag-
nostic workup of  patients with NAFLD, and it remains 
one of  the major reasons for performing liver biopsy in 
this population. After a large number of  studies was un-
dertaken in hepatitis C patients that tried either to design 
tests and scoring systems using combinations of  read-
ily available clinical and biochemical parameters, or to 
find specific biomarkers of  fibrosis processes that would 
adequately correspond to liver biopsy findings, similar at-
tempts were made as well in populations of  patients with 
NAFLD. Generally, while showing good accuracy in de-
tection of  advanced fibrosis or cirrhosis, all of  these tests 
demonstrate significantly lower sensitivities in predicting 
the presence of  mild or moderate fibrosis. The problem 
lies in the fact that this is exactly the group of  patients 
that would benefit most from therapeutic interventions, 
before significant fibrosis has already developed, and they 
therefore require early diagnosis.
Hyaluronic acid and other markers of extracellular 
matrix turnover 
Hyaluronic acid is a component of  the extracellular ma-
trix that can be measured in serum, where it partially 
enters through lymphatics. Serum levels are dependent on 
production, which increases with increased collagen syn-
thesis, as well as degradation, which takes course in liver 
sinusoidal endothelial cells after binding to specific recep-
tors. With progression of  liver fibrosis, both increased 
production of  collagen and decreased function of  sinu-
soidal endothelial cells lead to elevation of  hyaluronic 
acid serum levels.
Several groups have so far evaluated the potential use 
of  hyaluronic acid levels in diagnosis of  NASH-related 
fibrosis. Suzuki et al[62] investigated the potential of  hy-
aluronic acid for use in diagnosing fibrosis in a cohort 
of  79 patients with NAFLD and various degrees of  
fibrosis. The hyaluronic acid serum levels demonstrated 
good correlation with the degree of  hepatic fibrosis, and 
significant difference was noted especially when compar-
ing mild to moderate (Stages 0-2) with severe fibrosis or 
cirrhosis (Stages 3-4). The calculated AUROC for severe 
fibrosis was 0.89 (95% CI 0.81-0.97), and at the optimal 
cut-off  value of  46.1 ng/mL sensitivity was 85% (95% 
CI 62%-97%) and specificity 80% (95% CI 67%-89%). 
When a prevalence of  severe fibrosis among NAFLD 
patients was assumed to be 20% (approximate of  usual 
patient population at referral centers), the corresponding 
positive predictive value was 51% (95% CI 39%-68%) and 
negative predictive value 95% (95% CI 91%-100%). Ac-
curacy for diagnosing mild fibrosis (Stage 1) was low and 
the number of  patients with moderate fibrosis (Stage 2) 
was inadequate for valid analysis. Another study evalu-
ated hyaluronic acid and laminin levels in 50 patients with 
NASH, of  whom 23 had some degree of  fibrosis and 27 
had no fibrosis on liver biopsy[63]. Subjects with NASH 
and fibrosis had significantly higher hyaluronic acid and 
laminin levels than those without fibrosis, and AUROC 
and diagnostic performance of  both of  these markers 
was calculated for differentiating between presence and 
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absence of  fibrosis, showing excellent diagnostic accuracy 
of  hyaluronic acid at the cut-off  value of  148.8 ng/mL 
(reported sensitivity and specificity was over 95%). In 
the fibrosis group, levels of  hyaluronic acid significantly 
increased with rising fibrosis stages, however the accuracy 
for distinguishing different fibrosis stages was not tested 
due to small patient numbers. Sakugawa et al[64] investigat-
ed the levels of  hyaluronic acid and type Ⅵ collagen 7S 
domain in a population of  112 patients with NAFLD, of  
whom 70 were classified as NASH. On regression analy-
sis, both markers were independently associated with the 
presence of  NASH or severe fibrosis, but demonstrated 
sensitivity and specificity for severe fibrosis in the range 
of  70%-80%. However, if  both markers were negative in 
a given patient, severe fibrosis was highly unlikely to be 
present (negative predictive value 95.2%).
Although some of  these results look very promising, 
studies are still lacking in power, and the proposed cut-
off  values and calculated diagnostic accuracies are quite 
heterogeneous, which may be due to other factors in 
addition to difference in sample size, like difference in 
measurement methods and studied populations. Another 
important aspect of  clinical usefulness of  hyaluronic acid 
and other serum markers of  fibrosis that hasn’t yet been 
investigated is the question of  sensitivity to longitudinal 
changes in fibrosis of  liver parenchyma, which could po-
tentially enable noninvasive patient follow-up and evalua-
tion of  treatment effects.
Multicomponent panels
FibroTest is a copyrighted panel developed by the French 
group who originally conceived it for diagnosis of  liver 
fibrosis in hepatitis C, where it has subsequently been 
extensively studied. It includes 5 biochemical parameters 
(α2-macroglobulin, apolipoprotein A1, haptoglobin, 
total bilirubin and GGT) that are incorporated into a 
patented formula. More recently, the authors of  the panel 
conducted a study that thoroughly evaluated diagnostic 
performance of  FibroTest in the setting of  NAFLD by 
including 267 patients and a large number of  healthy 
controls[65]. Fibrosis stage was determined according to 
Kleiner et al[59], and advanced fibrosis included stages 
F2-F4 (perisinusoidal and portal/periportal fibrosis, 
bridging fibrosis and cirrhosis). Mean FibroTest value 
steadily increased with increasing fibrosis stage, and cal-
culated AUROC for advanced fibrosis was 0.86 (95% 
CI 0.77-0.91), while it was 0.92 (95% CI 0.83-0.96) for 
bridging fibrosis or cirrhosis (F3-F4). A FibroTest cut-
off  score of  0.30 had 77% sensitivity and 90% negative 
predictive value, and score of  0.70 had 98% specificity 
and 76% positive predictive value for advanced fibrosis. 
As expected, performance was even better in detection 
of  F3-F4, with 92% sensitivity and 98% negative predic-
tive value. In addition to one third of  patients having 
the value that fell between these two cut-offs and thus a 
nondiagnostic test result, other causes of  FibroTest fail-
ure were analyzed and included Gilbert’s syndrome, acute 
inflammation, and abnormal apolipoprotein A1 that was 
related to dyslipidaemia. 
Another large multicenter study by a different group 
was undertaken and included a total of  733 patients di-
vided in 2 groups in an attempt to develop and validate a 
noninvasive scoring system that would separate NAFLD 
patients with and without advanced liver fibrosis[66]. The 
score was named NAFLD fibrosis score and included a 
formula with 6 variables (age, hyperglycemia, body mass 
index, platelet count, albumin and AST/ALT ratio), se-
lected based on results of  multivariate analysis. Biopsy 
was also scored according to Kleiner et al[59], but the di-
agnostic goal of  advanced fibrosis included only Stages 
F3 and F4. AUROC values were 0.88 in estimation and 
0.82 in validation set, and two cut-off  points were deter-
mined similarly to the previously mentioned study. Using 
the low cut-off  point, negative predictive value of  the 
score was 93% in estimation group and 88% in valida-
tion group, while with the high cut-off  point positive 
predictive value was 90% in estimation group and 82% in 
validation group. Only 25% of  patients had score values 
between the cut-offs and would thus be considered as 
“indeterminate” and still require liver biopsy after this 
noninvasive test was performed.
After the European Liver Fibrosis Group developed 
an algorithm that included age, tissue inhibitor of  matrix 
metalloproteinase 1, hyaluronic acid and aminoterminal 
peptide of  pro-collagen Ⅲ and tested its performance 
in diagnosing significant fibrosis in a large cohort of  pa-
tients with various chronic liver diseases, another study 
was undertaken more recently that investigated perfor-
mance of  this panel specifically in NAFLD patients[67,68]. 
The original panel was modified by excluding age and 
naming it enhanced liver fibrosis panel (ELF), and its 
diagnostic performance was tested in a cohort of  192 
patients. The ELF panel had very good performance in 
distinguishing severe fibrosis (Stage F3-F4) with an AU-
ROC of  0.90 (95% CI 0.84-0.96), while AUROC for de-
tecting moderate and severe fibrosis together (F2-F4) was 
0.82 (95% CI 0.75-0.88). Diagnostic accuracy varied with 
various cut-off  points tested, and if  cut-offs with 90% 
sensitivity and specificity for severe fibrosis detection 
were selected, 86% of  study patients would have avoided 
a liver biopsy, with 76% correctly classified. The study 
also suggested that the addition of  simple parameters, the 
ones included in previously mentioned NAFLD fibrosis 
score, could augment the diagnostic performance of  the 
ELF panel, although additional studies with larger sample 
size would be required to confirm this.
CONCLUSION
Due to the very high prevalence of  the disease and nu-
merous difficulties related to establishing the diagnosis, 
NAFLD remains undiagnosed or incompletely defined 
in a large number of  cases. Therefore, the search for the 
means to noninvasive diagnosis of  different forms of  
NAFLD is a matter of  uttermost importance. It is gain-
ing even greater significance in the light of  recent ad-
vances in the treatment of  NASH, as the research efforts 
are finally starting to provide us with definite treatment 
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options. Recently published study with vitamin E and pi-
oglitazone, as well as other current treatment trials place 
the necessity of  establishing a correct diagnosis and not 
missing NASH in a whole different perspective[12]. Fur-
thermore, given the proportion of  population with fatty 
liver and the fact that the presence of  NASH in a given 
patient is often not linked with elevation in liver enzymes, 
the number of  patients in need of  a screening becomes 
daunting. After the insight in all of  the aforementioned 
studies, we can see that some have indeed come very 
close and demonstrated very good diagnostic perfor-
mance of  certain noninvasive tools. However, the gold 
standard used in almost all of  the studies is liver biopsy, 
and the question that remains is whether we are actually 
able to accurately assess the performance of  noninvasive 
methods when the gold standard by itself  has significant 
flaws. These flaws were very clearly demonstrated in a 
study of  sampling variability in NAFLD by Ratziu et al[11]. 
One can also pose the question: have we maybe found an 
excellent noninvasive tool already, but are ignorant of  the 
fact due to our incapability to actually see “the absolute 
truth”? This question has been addressed in a study by 
Mehta et al[69], who calculated the AUROC for a hypo-
thetic liver histology surrogate marker against the biopsy 
for a range of  possible performances of  both tests. The 
authors found that an ideal marker (99% accuracy) could 
in the best possible setting (sensitivity and specificity of  
biopsy 90%, prevalence of  significant disease 40%) have 
an AUROC of  not more than 0.90. This may mean that, 
unless an alternative gold standard is found, we might as 
well be in pursuit of  something that isn’t there.
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